» Articles » PMID: 37223529

Mechanisms of NLRP3 Inflammasome-mediated Hepatic Stellate Cell Activation: Therapeutic Potential for Liver Fibrosis

Overview
Journal Genes Dis
Date 2023 May 24
PMID 37223529
Authors
Affiliations
Soon will be listed here.
Abstract

The liver injury leads to an inflammatory response, which causes the activation of hepatic stellate cells (HSCs) that further secrete ECM proteins and play an important role in liver fibrosis. Moreover, the inflammatory response is a driving force for fibrogenesis, which is triggered by many types of injuries. Exaggerated inflammatory immune responses are mediated by cytoplasmic protein complexes known as inflammasomes, which are involved in many chronic liver diseases. Inflammasomes are pattern recognition receptors (PRRs) that can sense any microbial motifs known as pathogen-associated molecular patterns (PAMPs), and host- or environmental-derived stress signals known as damage-associated molecular patterns (DAMPs). The inflammasomes cause caspase-mediated proteolytic cleavage of pro-IL-1β and pro-IL-18 into active IL-1β and IL-18. In this review, we provide a comprehensive summary of the important roles of NLRP3 inflammasome in the pathogenesis of liver fibrosis with an emphasis on several direct and indirect pathways responsible for the NLRP3 inflammasome-mediated HSCs activation and fibrogenesis. In addition, we discuss the general pharmacological and genetics strategies for the inhibition of NLRP3 inflammasome activation and its downstream signaling with examples of emerging pharmacotherapeutics, targeting the NLRP3 inflammasome signaling as well as a possible way to develop effective and safer NLRP3 inflammasome inhibitors.

Citing Articles

Clusterin deficiency exacerbates cholestatic liver disease through ER stress and NLRP3 inflammasome activation.

Seo H, Park J, Lee S, Lee H, Han E, Hwang J Cell Biosci. 2025; 15(1):36.

PMID: 40089787 DOI: 10.1186/s13578-025-01376-z.


Metabolism of hepatic stellate cells in chronic liver diseases: emerging molecular and therapeutic interventions.

Yan M, Cui Y, Xiang Q Theranostics. 2025; 15(5):1715-1740.

PMID: 39897543 PMC: 11780521. DOI: 10.7150/thno.106597.


NLRP3 inflammasome constrains liver regeneration through impairing MerTK-mediated macrophage efferocytosis.

Wei S, Guan G, Luan X, Yu C, Miao L, Yuan X Sci Adv. 2025; 11(1):eadq5786.

PMID: 39742469 PMC: 11691640. DOI: 10.1126/sciadv.adq5786.


Navigating from cellular phenotypic screen to clinical candidate: selective targeting of the NLRP3 inflammasome.

Matico R, Grauwen K, Chauhan D, Yu X, Abdiaj I, Adhikary S EMBO Mol Med. 2024; 17(1):54-84.

PMID: 39653810 PMC: 11730736. DOI: 10.1038/s44321-024-00181-4.


The role of macrophages in liver fibrosis: composition, heterogeneity, and therapeutic strategies.

Ma X, Qiu J, Zou S, Tan L, Miao T Front Immunol. 2024; 15:1494250.

PMID: 39635524 PMC: 11616179. DOI: 10.3389/fimmu.2024.1494250.


References
1.
Han Y, Ramprasath T, Zou M . β-hydroxybutyrate and its metabolic effects on age-associated pathology. Exp Mol Med. 2020; 52(4):548-555. PMC: 7210293. DOI: 10.1038/s12276-020-0415-z. View

2.
Jin H, Lian N, Zhang F, Bian M, Chen X, Zhang C . Inhibition of YAP signaling contributes to senescence of hepatic stellate cells induced by tetramethylpyrazine. Eur J Pharm Sci. 2016; 96:323-333. DOI: 10.1016/j.ejps.2016.10.002. View

3.
Dempsey L . Sirtuin regulation of NLRP3. Nat Immunol. 2020; 21(4):358. DOI: 10.1038/s41590-020-0657-x. View

4.
Liu W, Guo W, Wu J, Luo Q, Tao F, Gu Y . A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharmacol. 2013; 85(10):1504-12. DOI: 10.1016/j.bcp.2013.03.008. View

5.
Tang N, Zhang Y, Ying W, Yao X . Interleukin-1β upregulates matrix metalloproteinase-13 gene expression via c-Jun N-terminal kinase and p38 MAPK pathways in rat hepatic stellate cells. Mol Med Rep. 2013; 8(6):1861-5. DOI: 10.3892/mmr.2013.1719. View